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aneurysm is associated with adverse late outcomes
J.E. Jones, M.D. Atkins, D.C. Brewster, T.K. Chung, C.J. Kwolek, G.M.
LaMuraglia, T.M. Hodgman and R.P. Cambria
Objective. Type 2 endoleak occurs in up to 20% of patients after endovascular
aneurysm repair (EVAR), but its long-term significance is debated. We re-
viewed our experience to evaluate late outcomes associated with type 2
endoleak.
Methods. During the interval January 1994 to December 2005, 873 patients un-
derwent EVAR. Computed tomography (CT) scan assessment was performed
1month of the operation and at least annually thereafter. Sequential 6-month
CTscan follow-up was adopted for those patients with persistent type 2 endo-
leaks, and reintervention was limited to those with sac enlargement >5 mm.
Study end points included overall survival, aneurysm sac growth, reinterven-
tion rate, conversion to open repair, and abdominal aortic aneurysm (AAA)
rupture. Preoperative variables and anatomic factors potentially associated
with these endpoints were assessed using multivariate analysis.
Results. We identified 164 (18.9%) patients with early (at the first follow-up
CT scan) type 2 endoleaks. Mean follow-up was 32.6 months. In 131
(79.9%) early type 2 endoleaks, complete and permanent leak resolution oc-
curred 6 months. Endoleaks persisted in 33 patients (3.8% of total patients;
20.1% of early type 2 endoleaks) for >6 months. Transient type 2 endoleak
(those that resolved 6 months of EVAR) was not associated with adverse
late outcomes. In contrast, persistent endoleak was associated with several
adverse outcomes. AAA-related death was not significantly different be-
tween patients with and without a type 2 endoleak (P ¼ .78). When evaluat-
ing patients with no early endoleak vs persistent endoleak, freedom from sac
expansion at 1, 3, and 5 years was 99.2%, 97.6%, and 94.9% (no leak) vs 88.1%,
48.0%, and 28.0% (persistent) (P < .001). Patients with persistent endoleak
were at increased risk for aneurysm sac growth vs patients without endoleak
(odds ratio [OR], 25.9; 95% confidence interval [CI] 11.8 to 57.4; P < .001). Pa-
tients with a persistent endoleak also had a significantly increased rate of re-
intervention (OR, 19.0; 95% CI, 8.0 to 44.7); P < .001). Finally, aneurysm
rupture occurred in 4 patients with type 2 endoleaks. Freedom from rupture
at 1, 3, and 5 years for patients with a persistent type 2 endoleak was 96.8%,
96.8%, and 91.1% vs 99.8%, 98.5%, and 97.4% for patients without a type 2
endoleak. Multivariate analysis demonstrated persistent type 2 endoleak to
be a significant predictor of aneurysm rupture (P ¼ .03).
Conclusions. Persistent type 2 endoleak is associated with an increased inci-
dence of adverse outcomes, including aneurysm sac growth, the need for con-
version to open repair, reintervention rate, and rupture. These data suggest that
patients with persistent type 2 endoleak (>6 months) should be considered for
more frequent follow-up or a more aggressive approach to reintervention.
Long-term postplacement cost after endovascular aneurysm repair
R.E. Noll Jr, B.H. Tonnessen, K. Mannava, S.R. Money and
W.C. Sternbergh III
Background. Previous studies have demonstrated that the initial hospital cost
associated with endovascular aneurysm repair (EVAR) is approximately
$20,000. However, the cost of long-term surveillance and secondary proce-
dures is poorly characterized.
Methods. Between December 1998 and June 2006, 259 patients underwent
EVAR for infrarenal aneurysms at a single institution. Follow-up costs were
calculated using a relative value unit based hospital cost accounting system,
which incorporates departmental direct and indirect costs. Institutional over-
head costs were included using a conversion factor. Costs for professional
services were determined by a cost-to-charge ratio, and outpatient visits
were calculated with a time-based formula. Year 2006 costs were applied to
prior years. To minimize costs associated with the early learning curve, the
initial 50 EVAR patients between December 1995 and 1998 were excluded.
* Full articles available online at www.jvascsurg.orgYEJVS2686_2669_proof 
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Results. The mean follow-up after EVAR for 136 patients was 34.7  1.8
months. The cumulative 5-year postplacement cost per patient was $11,351.
The 27 patients (19.9%) who required secondary procedures had a 5-year cu-
mulative cost of $31,696 compared with $3668 for 109 patients without sec-
ondary procedures (8.6-fold increase, P < .05). The 5-year cost for patients
with endoleak was $26,739 compared with $5706 for those without endoleak
(4.7-fold increase, P < .05). Overall, major cost components were 57.4% for
secondary procedures and 32.5% for radiologic studies.
Conclusions. During a 5-year period, the postplacement cost of EVAR in-
creases the global cost by 44%. The subgroups of patients with endoleaks
and those requiring secondary procedures generate a disproportionate share
of postplacement costs. Efforts at minimizing cost should emphasize techni-
cal and device modifications aimed at reducing endoleaks and the need for
secondary procedures.
Carotid intraplaque hemorrhage detected by magnetic resonance
imaging predicts embolization during carotid endarterectomy
N. Altaf, A. Beech, S.D. Goode, J.R. Gladman, A.R. Moody, D.P. Auer and
S.T. MacSweeney
Background. Microembolization detected during the dissection phase of ca-
rotid endarterectomy (CEA) is associated with plaque instability and might
be associated with perioperative morbidity. Intraplaque hemorrhage is found
in unstable plaques and is detectable using magnetic resonance imaging
(MRI). We aimed to ascertain whether intraplaque hemorrhage as seen on ca-
rotid MRI predicts particulate embolization in the dissection phase of CEA.
Methods. Patients with high-grade symptomatic carotid stenosis undergoing
CEA were prospectively enrolled. All underwent preoperative MRI assess-
ment of the carotid arteries for intraplaque hemorrhage and transcranial
Doppler scanning during the dissection phase of the CEA to assess the pres-
ence of microembolic signals. Associations between intraplaque hemorrhage
and intraoperative microembolic signals were studied.
Results. Analysis was undertaken on 60 participants; of these, 36 (60%)
showed ipsilateral carotid MRI intraplaque hemorrhage, and 24 (40%) did
not. Microembolic signals were detected during the dissection phase in 23
(38.3%) participants, and 19 had MRI-detected intraplaque hemorrhage.
The association between carotid intraplaque hemorrhage and the presence
of dissection phase microembolic signals was significant (odds ratio [OR],
5.6; 95% confidence interval [CI], 1.6 to 19.7, P ¼ .007), even after controlling
for age, sex, individual surgeon, degree of stenosis, and delay from symptom
to CEA (adjusted OR, 5.8; 95% CI, 1.1 to 30.4, P ¼ .037).
Conclusion. Intraplaque hemorrhage as detected by carotid MRI predicts
particulate embolization during the dissection phase of CEA. This imaging
technique can be used to identify patients with increased intraoperative
thromboembolic risk, and this could influence preventive strategies.
Frequency of transient ipsilateral vocal cord paralysis in patients
undergoing carotid endarterectomy under local anesthesia
F. Thermann, J. Ukkat, E. John, H. Dralle and M. Brauckhoff
Background. Especially because of improvements in clinical neurologic mon-
itoring, carotid endarterectomy done under local anesthesia has become the
technique of choice in several centers. Temporary ipsilateral vocal nerve
palsies due to local anesthetics have been described, however. Such compli-
cations are most important in situations where there is a pre-existing contra-
lateral paralysis. We therefore examined the effect of local anesthesia on vocal
cord function to better understand its possible consequences.
Methods. This prospective study included 28 patients undergoing carotid
endarterectomy under local anesthesia. Vocal cord function was evaluated
before, during, and after surgery (postoperative day 1) using flexible31 May 2007  118/120
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119Abstractslaryngoscopy. Anesthesia was performed by injecting 20 to 40 mL of a mixture
of long-acting (ropivacaine) and short-acting (prilocaine) anesthetic.
Results. All patients had normal vocal cord function preoperatively. Twelve
patients (43%) were found to have intraoperative ipsilateral vocal cord paral-
ysis. It resolved in all cases 24 hours. There were no significant differences
in operating time or volume or frequency of anesthetic administration in pa-
tients with temporary vocal cord paralysis compared with those without.
Conclusion. Local anesthesia led to temporary ipsilateral vocal cord paralysis
in almost half of these patients. Because pre-existing paralysis is of a relevant
frequency (up to 3%), a preoperative evaluation of vocal cord function before
carotid endarterectomy under local anesthesia is recommended to avoid in-
traoperative bilateral paralysis. In patients with preoperative contralateral
vocal cord paralysis, surgery under general anesthesia should be considered.
Transcervical carotid stenting with flow reversal protection: Experience
in high-risk patients
M. Matas, B. Alvarez, M. Ribo, C. Molina, J. Maeso and J. Alvarez-Sabin
Background. Carotid angioplasty and stenting (CAS) with cerebral embolic
protection is a safe alternative to carotid endarterectomy in high-risk patients.
Among the various systems proposed for cerebral protection, transcervical
CAS avoids crossing the lesion without protection and eliminates the compli-
cations associated with transfemoral access. This study analyzes our experi-
ence and the results obtained with a transcervical stenting technique for
carotid revascularization.
Methods. From January 2005 to June 2006, 62 CAS were performed in our cen-
ter in high-risk patients with >70% stenosis (38.7% had a previous neurologic
event and 61.3% were asymptomatic). The indications for CAS were severe
heart disease (45.1%), severe pulmonary disease (6.4%), paralysis of the contra-
lateral laryngeal nerve (6.4%), recurrent stenosis (3.2%), and high carotid le-
sion (1.6%). Twenty-one patients were >80 years old. A complete neurologic
examination was performed by a stroke neurologist in all patients before
and after stenting. The protection system used was carotid flow reversal by
transcervical access. Transcranial Doppler monitoring was done during the
procedure in 35 patients. We analyzed technical success, the presence of
high-intensity transient signals during the procedure, neurologic morbidity
and mortality at 30 days and 6 months, and stent patency at 6 months (range,
1 to 18 months). Technical success was 96.8%. Perioperative high-intensity
transient signals were observed in two patients (5.7%). In the immediate post-
operative period, one patient had a transient ischemic attack of the anterior ce-
rebral artery and another had a stroke, with contralateral hemiplegia. At 48
hours after discharge, a third patient returned to the hospital with a severe ce-
rebral hemorrhage that required surgical drainage; hence, neurologic morbid-
ity was 4.9%. There were no deaths at 6 months. Among the total, 98.4% of the
stents remained patent, two showed restenosis of 50% to 70%, and one reste-
nosis of>70%. No patients presented a neurologic event during the follow-up.
Conclusions. Transcervical carotid artery stenting with flow reversal cerebral
protection is a relatively simple, safe technique that avoids instrumentation of
the aortic arch and crossing the target lesion without protection. It is less ex-
pensive than techniques requiring a filter device and provides excellent out-
come with an acceptable incidence of complications.
Atheroembolism during percutaneous renal artery revascularization
M.S. Edwards, M.A. Corriere, T.E. Craven, X.M. Pan, J.H. Rapp, J.D. Pearce,
N.B. Mertaugh and K.J. Hansen
Introduction. Atheroembolization during renal artery angioplasty and stent-
ing (RA-PTAS) has been postulated as a cause for the inferior renal function
results observed when compared with those with surgical revascularization.
To further characterize procedure-associated atheroembolism, we analyzed
recovered atheroembolic debris and clinical data from patients undergoing
RA-PTAS with distal embolic protection (DEP).
Methods. RA-PTAS procedures were performed with DEP using a commer-
cially available temporary balloon occlusion and aspiration catheter systembe-
tween July 2005 andDecember 2006. Following RA-PTAS but prior to deflation
of the distal occlusion balloon, the static column of blood proximal to the bal-
loon was aspirated and submitted for embolic particle analysis. Angiograms,demographics, and laboratory data were reviewed. Glomerular filtration rate
(eGFR)was estimated before RA-PTAS and at 4 to 8weeks postintervention us-
ing the abbreviatedModification ofDiet inRenalDisease formula.Associations
between clinical factors, capturedparticle counts, and changes in renal function
were examined using univariate techniques and multiple linear regression.
Results. Twenty-eight RA-PTAS procedures were performed with DEP. Mean
total number of embolic particles counted per procedure was 2033  1553 for
particles 20-60 mm and 265  132 for particles >60 mm. Significant positive as-
sociations with quantity of captured particles 20 to 60 mm were observed for
African American race (P ¼ .002), predilation (P ¼ .005), and stent diameter
(P < .001); a significant negative association was observed for preoperative
aspirin use (P ¼ .016). Quantity of captured particles >60 mm was positively
associated with ratio of stent to renal artery diameter (P ¼ .009). Change in
eGFR was positively associated with preoperative aspirin use (P ¼ .006)
and preoperative eGFR (P < .001), while a negative association was observed
for captured particle counts >60 mm (P ¼ .015).
Conclusion. These results demonstrate the liberation of thousands of athe-
roembolic particles during RA-PTAS. Clinical, anatomic, and device-related
factors may be predictive of procedural embolization, and increasing cap-
tured particle counts >60 mm were associated with inferior renal function re-
sults. Further investigation is warranted to establish relationships between
atheroembolism, end organ functional impairment, and clinical responses.
Prognostic value of ankle-brachial index and dobutamine stress
echocardiography for cardiovascular morbidity and all-cause mortality
in patients with peripheral arterial disease
M.R. Thatipelli, P.A. Pellikka, R.D. McBane, T.W. Rooke, G.A. Rosales,
D. Hodge, R.M. Herges and W.E. Wysokinski
Background. Peripheral arterial disease (PAD) is associated with an excessive
risk for cardiovascular events and mortality. To determine measures prognos-
tic of adverse events, ankle-brachial index (ABI) was compared with dobut-
amine stress echocardiography (DSE) in patients referred to our vascular
center for the evaluation of PAD.
Methods. The medical records of consecutive patients referred for the concur-
rent evaluation of PAD and coronary artery disease (CAD) between 1992 and
1995 were reviewed for subsequent cardiovascular events and death.
Results. Among 395 patients (mean age, 69.7  9.6 years; 40% women), 341
had abnormal ABI and 268 had abnormal DSE (95 fixed and 173 stress-
induced wall motion abnormalities). During a mean follow-up of 4.7 years,
27.3% of patients experienced a cardiovascular event, and 39.4% died. By
multivariate analysis, ABI provided the strongest prediction of all-cause mor-
tality (hazard ratio [HR], 2.34; 95% confidence interval [CI], 1.36 to 4.05;
P ¼ .002). Conversely, DSE with inducible or fixed wall motion abnormalities
showed no association with cardiovascular events or increased mortality in
multivariate analysis. The only DSE variable independently predictive of
mortality was decreased left ventricular ejection fraction (<50%) at peak
stress (HR, 1.70; 95% CI, 1.22 to 2.36; P ¼ .002). Statin and aspirin therapy,
but not b-blockers, were protective. There was no relation between ABI
and wall motion index score at rest or after stress.
Conclusions. In high-risk patients referred to our vascular center for the eval-
uation of PAD, the assessment of ABI provided a strong independent predic-
tion of all-cause mortality. Therefore, proper interpretation of this simple,
affordable, and reproducible measure extends beyond the assessment of
PAD severity. Although a poor left ventricular response to dobutamine was
also predictive, other echo variables were not.
Evaluation of the efficacy of the transposed upper arm arteriovenous
fistula: A single institutional review of 190 basilic and cephalic vein
transposition procedures
K. Woo, A. Farber, G. Doros, K. Killeen and S. Kohanzadeh
Introduction. Although autogenous brachial-basilic upper arm transpositions
(BVT) have been extensively utilized, there has been significant disparity in
published patency rates. Very little is known about the efficacy of autogenous
brachial-cephalic upper arm transpositions (CVT). We evaluated our experi-
ence with transposed upper arm arteriovenous fistulas (tAVF) in order toEur J Vasc Endovasc Surg Vol 34, July 2007
120 Abstractsassess patency and identify factors that affect efficacy. We then compared our
tAVF patients with a cohort of upper arm arteriovenous grafts (AVG).
Methods. A retrospective review was conducted of tAVF performed at our in-
stitution from 1998 to 2004. The tAVF group consisted of 119 BVT and 71 CVT
procedures. We compared these with 164 AVG. tAVF were placed only for
veins 2.5 mm in diameter by duplex ultrasonography.
Results. Mean follow-up was 28 months. With the exception of mean vein di-
ameter, the patients in the BVTand CVT groups had similar demographic pa-
rameters and complication rates. Primary and secondary patency rates were
52% and 62% at 5 years for BVT and 40% and 46% at 5 years for CVT, respec-
tively (P ¼ NS). Multivariate analysis revealed that hemodialysis dependence
at the time of fistula placement and history of previous upper arm access
independently affected primary patency. History of upper torso dialysis cath-
eters independently affected secondary patency. Comparison of the tAVF and
AVG groups revealed that tAVF patients were significantly younger, moreEur J Vasc Endovasc Surg Vol 34, July 2007likely to be male, less likely to be African American (AA) and less likely to
have a history of previous AV access. The primary patency rate for tAVF
was significantly higher than for AVG: 48% vs 14% at 5 years (P < .001).
The secondary patency rate for tAVF was also significantly higher than for
AVG: 57% vs 17% at 5 years (P < .001). Among the tAVF procedures, 9%
required one or more revisions to maintain secondary patency, compared
to 51% with the AVG group (P < .001). Multivariate analysis revealed that
presence of AVG and a history of previous upper arm access negatively
affected primary and secondary patency.
Conclusions. Autogenous BVT and CVT have similar, high patency rates.
Transposed upper arm arteriovenous fistulas have higher patency rates
than upper arm AVG and require significantly fewer revisions. Our data
strongly support the contention that as long as the patient is a candidate
for an upper arm tAVF, based on anatomical criteria, a tAVF should always
be considered before an AVG.
